Neuropathic pain responds better to increased doses of pregabalin: an in-depth analysis of flexible-dose clinical trials
Received 9 December 2016
Accepted for publication 17 May 2017
Published 26 July 2017 Volume 2017:10 Pages 1769—1776
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr E. Alfonso Romero-Sandoval
Michael Serpell,1 Mark Latymer,2 Mary Almas,3 Marie Ortiz,4 Bruce Parsons,4 Rita Prieto5
1University Department of Anaesthesia, Stobhill Ambulatory Care Hospital, Glasgow, 2Pfizer Ltd, Tadworth, UK; 3Pfizer, Groton, CT, 4Pfizer, New York, NY, USA; 5Pfizer GEP SLU, Madrid, Spain
Background: Pregabalin is an effective treatment option for many patients with neuropathic pain. Higher doses of pregabalin have been shown to be more effective in improving pain outcomes but, in practice, failing to appropriately increase the dose can leave patients under-treated.
Methods: This was a pooled analysis of 6 flexible-dose clinical trials of pregabalin in patients with neuropathic pain (diabetic peripheral neuropathy, peripheral herpetic neuralgia, posttraumatic pain, or postsurgical pain). Patients were divided into “dose pathway” groups based on their weekly pregabalin dose from the start of their trial to the first week of their maintenance phase. These were: 150 mg/day only; 150 to 300 mg/day; 150 to 300 to 450 mg/day; 150 to 300 to 450 to 600 mg/day; 150 to 300 to 600 mg/day; 300 to 600 mg/day. Pain outcomes assessed for each group at each new dose were proportion of 30% and 50% responders (≥30% or ≥50% reduction in mean pain score from baseline) and mean change in pain score. Percent change in mean pain score from baseline was assessed using a marginal structural model.
Results: Seven hundred and sixty-one patients treated with flexible-dose pregabalin were included in the analysis. For each dose pathway group, there was a notably greater proportion of 30% and 50% responders and change in pain score, at each escalating dose. As assessed by the marginal structural model, higher doses of pregabalin were estimated to result in a significantly greater change in mean pain score at each week. This dose response with flexible-dose pregabalin was consistent with that previously observed with fixed-dose pregabalin.
Conclusion: Many patients who do not respond to lower doses of pregabalin will respond with notable improvements in pain outcomes when the dose is escalated. These data should encourage physicians treating patients with neuropathic pain to escalate pregabalin to the dose that delivers optimal analgesia and tolerable side effects.
Keywords: neuropathic pain, pregabalin, dosing
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Other articles by this author:
Parsons B, Argoff CE, Clair A, Emir B
Published Date: 7 October 2016
Temporal analysis of pain responders and common adverse events: when do these first appear following treatment with pregabalin
Parsons B, Emir B, Clair A
Published Date: 29 June 2015
Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials
Freeman R, Emir B, Parsons B
Published Date: 1 June 2015